Embracing Differences: Our journey to diversity, equity, and inclusion
Embracing Differences: Our journey to diversity, equity, and inclusion
Search
A Holistic Approach to Cardio-Renal-Metabolic Care | Boehringer Ingelheim US
Our Blueprint for Constructing a Holistic Approach to Cardio-renal-metabolic Care
FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US
Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia
Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia
Why role models matter for black veterinarians: One doctor's story
Why role models matter for black veterinarians: One doctor's story
Cookie Statement
Cookie Statement
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
Supporting People with Diabetes and Related Conditions in the Time of COVID-19
Supporting People with Diabetes and Related Conditions in the Time of COVID-19
Cardiologists at the Heart of Cardio-Renal-Metabolic Care | Boehringer Ingelheim US
Cardiologists at the Heart of Cardio-Renal-Metabolic Care
Let’s find CKD
More than 35 million Americas are living with chronic kidney disease (CKD), and most of them don’t know it. Early diagnosis of CKD needs to be a national priority.
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Health disparities in Black and African Americans
Addressing social determinants of health in cardio-kidney-metabolic care
A future without pills – could AI change the way we treat psychiatric diseases?
Dr Cornelia Dorner-Ciossek talks about how her work with smartphone tech could transform how we treat mental illness.
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US
Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
New effort to help improve C-R-M health outcomes
Boehringer Ingelheim sponsors American Heart Association's Cardiovascular Kidney Metabolic Health Intiative (CKMH)
The Role of Endocrinologists and PCPs in Diagnosing Chronic Kidney Disease
Mohamed Eid shares his perspective on the role endocrinologists and primary care professionals play in diagnosing chronic kidney disease.
Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US
Find out more on the BI PROZINC® (protamine zinc recombinant human insulin) for most canine diabetics, a breakthrough for pet owners with diabetic dogs.
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines
The findings demonstrate the benefit of clinic-level educational interventions